Spark Biomedical Receives FDA Breakthrough Device Designation for Infant Transcutaneous Auricular Neurostimulation (tAN™) Device, The Roo™ System
December 15, 2020 14:14 ET
|
Spark Biomedical
Dallas, Texas, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, Inc. announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Roo System: a...
Nine Foremost Pain Management Physicians Join the Spark Biomedical, Inc. Medical Advisory Board
August 28, 2020 09:30 ET
|
Spark Biomedical
Dallas, Texas, Aug. 28, 2020 (GLOBE NEWSWIRE) -- Spark Biomedical, developer of the Sparrow ™ Therapy System — a discrete, wearable, over-the-ear, medical device designed for opioid withdrawal...
Neurostimulation Clinical Trial Shows Promising Initial Results in Easing Opioid Withdrawal Symptoms in Newborns
August 05, 2020 11:14 ET
|
Spark Biomedical
Dallas, Texas, Aug. 05, 2020 (GLOBE NEWSWIRE) -- While instances of Neonatal Opioid Withdrawal Syndrome (NOWS) are still on the rise, and the eyes of the nation remain focused on a pandemic, the...